Does Network Health Cover Metformin?

What Is Network Health and How Does Its Drug Coverage Work?

Network Health is a Wisconsin-based insurer offering HMO and PPO products across commercial, Medicare Advantage, and Wisconsin Medicaid (BadgerCare Plus) lines. Its prescription drug benefits follow a tiered formulary structure that places cheap, well-established generics at the lowest cost-sharing level.

The Tier System Explained

Most Network Health formularies use four or five tiers. Tier 1 holds preferred generics, where a member's copay is typically $0 to $10 per fill. Tier 2 holds non-preferred generics and some preferred brands. Tiers 3 through 5 escalate in cost for brand-name, specialty, and high-cost biologics.

Metformin hydrochloride has been off-patent since the late 1990s. Because generic competition has driven the wholesale acquisition cost to well under $5 for a 90-day supply, virtually every large insurer slots it at Tier 1. Network Health follows that norm.

Medicare Part D Plans Through Network Health

Network Health offers Medicare Advantage Prescription Drug (MA-PD) plans in Wisconsin. Under the 2025 Medicare Part D redesign mandated by the Inflation Reduction Act, out-of-pocket costs for generic drugs in the coverage gap are capped, and metformin is widely placed in the $0 to $5 tier for low-income subsidy (LIS) enrollees. The Centers for Medicare and Medicaid Services publishes updated formulary data annually at cms.gov, and Network Health's specific plan formulary must legally be posted on its member portal.

Is Metformin FDA-Approved, and Does That Affect Coverage?

The FDA approved metformin hydrochloride (brand name Glucophage) in 1994 for the management of Type 2 diabetes mellitus in adults and children 10 years and older [1]. That approval history matters to insurers because FDA-approved indications for a generic drug almost never require prior authorization when the clinical indication is documented in the chart.

The Type 2 Diabetes Indication

For a member with a confirmed ICD-10 code of E11.x (Type 2 diabetes mellitus), Network Health will process a metformin claim at Tier 1 in most plan years without requiring additional documentation. A prescriber's note stating the diagnosis is sufficient. The American Diabetes Association's 2024 Standards of Care state: "Metformin, if tolerated and not contraindicated, is the preferred initial pharmacologic agent for type 2 diabetes" [2].

Prediabetes and Off-Label Use

Coverage becomes less predictable for prediabetes (ICD-10 R73.09) or off-label longevity indications. The ADA's 2024 guidelines note that metformin "may be considered" in adults with prediabetes, particularly those with BMI <35 kg/m² and age <60, but do not mandate it as first-line therapy [2]. Network Health commercial plans may cover this with a letter of medical necessity; Medicare Part D plans are prohibited by CMS rules from covering drugs for off-label indications unless supported by a compendia listing.

Clinical Evidence Supporting Metformin Prescribing

Understanding the evidence behind metformin helps patients and prescribers write stronger letters of medical necessity when coverage is disputed.

The UK Prospective Diabetes Study

The UK Prospective Diabetes Study (UKPDS 34, N=1,704 overweight patients with newly diagnosed Type 2 diabetes) showed that metformin reduced all-cause mortality by 36% and myocardial infarction by 39% compared with conventional diet therapy over a median 10.7 years of follow-up [3]. This landmark trial is the primary reason metformin remains a first-line agent more than 25 years after publication.

Diabetes Prevention Program

The Diabetes Prevention Program (DPP, N=3,234) randomized adults with prediabetes to intensive lifestyle intervention, metformin 850 mg twice daily, or placebo. Over 2.8 years, metformin reduced the incidence of Type 2 diabetes by 31% compared with placebo (P<0.001) [4]. The DPP Outcomes Study subsequently showed the benefit persisted at 15 years of follow-up [5]. These trial data are the backbone of any prior-authorization appeal for prediabetes coverage.

TAME Trial and Longevity Research

The Targeting Aging with Metformin (TAME) trial, funded by the American Federation for Aging Research and registered at ClinicalTrials.gov (NCT03781791), is currently enrolling approximately 3,000 adults aged 65 to 79 to test whether metformin 1,500 mg/day delays the onset of age-related diseases including cardiovascular disease, cancer, and dementia [6]. Results are expected in the late 2020s. Until TAME reports, longevity-only prescribing remains off-label and coverage under Network Health Medicare Part D plans is unlikely.

How to Verify Your Network Health Metformin Coverage

Verification takes under 10 minutes if you know where to look.

Step 1: Check the Online Formulary

Network Health posts its current drug list at its member portal. Search "metformin" or "metformin hydrochloride." Confirm the tier and any step-therapy requirements. Plans update formularies January 1 each year, so a check from last year may be outdated.

Step 2: Call Member Services

The member services number appears on the back of your insurance card. Ask specifically:

• What tier is metformin hydrochloride on my plan?
• Is a prior authorization required for my diagnosis code?
• What is my copay for a 30-day versus 90-day supply?
• Is mail-order pricing lower than retail?

Request the representative's name and employee ID, then document the date and time of the call. That record matters if you later need to appeal a denial.

Step 3: Have Your Prescriber Submit the Claim

A prescriber's electronic prior authorization (ePA) submitted with ICD-10 code E11.x or R73.09 and relevant lab values (fasting glucose, HbA1c) moves faster than a paper request. Most pharmacy benefit managers resolve ePA requests within 72 hours for non-urgent medications.

What If Network Health Denies Metformin Coverage?

Denials for a Tier 1 generic like metformin are uncommon but not impossible, particularly for off-label indications or if a claim was submitted with an incorrect code.

Common Denial Reasons

• Diagnosis code mismatch (wrong ICD-10)
• Off-label indication without compendia support
• Plan selected brand Glucophage instead of the generic (brands are rarely covered when the generic is available)
• Formulary exception needed for extended-release formulation (metformin ER may sit on Tier 2 on some plans)

Filing an Appeal

Under the Affordable Care Act, every insurer must provide a written explanation of denial and a clear appeal pathway. For Medicare Part D plans, CMS requires that urgent appeals be resolved within 24 hours and standard appeals within 7 days [7]. A letter of medical necessity from your prescriber citing the UKPDS and DPP data (see above) substantially strengthens a prediabetes appeal.

External Review

If Network Health upholds the denial after internal appeal, Wisconsin residents may request an independent external review through the Wisconsin Office of the Commissioner of Insurance. External reviews for prescription drug denials have a relatively high overturn rate when the clinical documentation is complete.

Cost of Metformin Without Insurance

If a denial occurs or you are in a coverage gap, metformin remains one of the cheapest drugs on the market.

Retail and Discount Pricing

At major pharmacy chains, a 90-day supply of metformin 500 mg (180 tablets) costs approximately $4 to $15 without insurance. GoodRx coupons frequently reduce this to under $10 in most Wisconsin ZIP codes.

Manufacturer Programs

Because metformin is fully generic, no manufacturer patient assistance program exists. However, the Health Resources and Services Administration (HRSA) maintains a directory of federally qualified health centers (FQHCs) that provide sliding-scale pharmacy services, accessible at findahealthcenter.hrsa.gov [8].

$4 Pharmacy Lists

Walmart, Walgreens, and Kroger all carry metformin on their $4 per-month generics lists. These programs are independent of insurance and available to any patient, regardless of coverage status.

Metformin Dosing and Formulations Covered by Network Health

Understanding which formulations sit on which tiers helps you select the right product when the prescriber writes the order.

Immediate-Release vs. Extended-Release

Metformin IR is the original formulation and the one most consistently placed on Tier 1. Metformin ER (sold under the brand name Glumetza or Fortamet) may sit on Tier 2 or require step therapy through IR first. The extended-release formulation was developed partly to reduce the gastrointestinal side effects (nausea, diarrhea) that affect up to 30% of patients starting on IR [9].

Liquid Formulation

Metformin oral solution (500 mg/5 mL) is available for patients who cannot swallow tablets. Coverage for the liquid is less consistent; some Network Health plans require a medical necessity note explaining why the tablet cannot be used.

Combination Products

Fixed-dose combinations such as metformin/sitagliptin (Janumet) or metformin/dapagliflozin (Xigduo XR) are brand-name products and sit on Tier 3 or higher. Prior authorization is often required. If a combination product is clinically necessary, the prescriber should document why two separate generics (e.g., metformin plus generic glipizide) would not suffice.

Metformin for Weight Management: Will Network Health Cover It?

Metformin is not FDA-approved as a weight-loss drug, and Network Health plans generally will not cover it when weight management is listed as the sole indication. However, many patients with Type 2 diabetes or prediabetes experience modest weight reduction as a secondary benefit.

Evidence on Weight Effects

A meta-analysis of 23 randomized controlled trials (N=2,021) published in Obesity Reviews found that metformin produced a mean weight reduction of 1.1 kg (95% CI: 0.5 to 1.7 kg) compared with placebo in non-diabetic overweight adults [10]. That effect is modest relative to GLP-1 receptor agonists such as semaglutide, which produced 14.9% mean weight loss in STEP-1 (N=1,961) at 68 weeks [11]. Insurers aware of the comparative data are unlikely to approve metformin as a stand-alone weight-loss agent when more effective alternatives exist.

Coding Strategy for Dual Indications

If a patient has both prediabetes (R73.09) and obesity (E66.x), submitting both ICD-10 codes on the claim improves the chance that at least one indication qualifies for coverage under the plan's medical policy.

Metformin Safety Profile and Contraindications That Affect Coverage

Renal Function Threshold

The FDA updated metformin's prescribing information in 2016 to allow use in patients with estimated glomerular filtration rate (eGFR) as low as 30 mL/min/1.73 m², with the recommendation to reduce the dose and monitor renal function every 3 to 6 months [1]. Prior to 2016, metformin was contraindicated at eGFR <60. Some older clinical decision tools still flag this, which can trigger an automated PA request. Providing current eGFR lab values with the prescription resolves most of these flags quickly.

Lactic Acidosis Risk

Metformin carries a boxed warning for lactic acidosis, a rare but serious complication occurring at an estimated rate of approximately 3 cases per 100,000 patient-years [9]. The risk is highest in patients with renal impairment, hepatic failure, or excessive alcohol use. Network Health utilization management tools may flag prescriptions for patients with relevant comorbidities for pharmacist review before dispensing.

Drug Interactions

Metformin has few significant drug interactions. Cimetidine and certain cationic drugs may increase metformin plasma levels by competing for renal tubular secretion. Iodinated contrast agents used in imaging studies can transiently worsen renal function; the FDA recommends holding metformin for 48 hours after intravascular contrast in patients with eGFR <60 [1].

Network Health Medicare Advantage vs. Commercial: Key Coverage Differences

| Feature | Commercial Plan | Medicare Advantage (MA-PD) | |---|---|---| | Formulary reset | January 1 annually | January 1 annually | | Typical metformin tier | Tier 1 | Tier 1 | | 30-day copay estimate | $0, $10 | $0, $5 (LIS enrollees $0) | | Prior auth for T2DM | Rarely required | Rarely required | | Off-label (longevity) | Possible with LMN | Not covered per CMS rules | | Mail-order option | Yes, often 90-day supply | Yes, often lower copay | | Gap coverage | N/A | 2025 IRA cap applies |

LMN = letter of medical necessity. IRA = Inflation Reduction Act of 2022.

Alternatives If Metformin Is Not Covered or Not Tolerated

If Network Health denies metformin or the patient cannot tolerate it, several other Tier 1 generics treat Type 2 diabetes effectively.

Sulfonylureas

Glipizide and glimepiride are first-generation and second-generation sulfonylureas, respectively, both available as generics on most Tier 1 formularies. The UKPDS showed that glibenclamide (a sulfonylurea) reduced microvascular complications in newly diagnosed Type 2 diabetes, though without the mortality benefit seen with metformin [3]. Hypoglycemia and weight gain are more frequent adverse effects compared with metformin.

Thiazolidinediones

Pioglitazone (brand: Actos) is available as a generic and often sits on Tier 1 or Tier 2. The PROactive trial (N=5,238) showed pioglitazone reduced the composite of death, non-fatal myocardial infarction, and stroke by 16% compared with placebo (P=0.027) in patients with Type 2 diabetes and established cardiovascular disease [12]. Fluid retention and a small increase in fracture risk are relevant considerations.

GLP-1 Receptor Agonists

Semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza) are highly effective but sit on Tier 3 or higher and almost always require prior authorization under Network Health. They are not Tier 1 alternatives in the same cost bracket as metformin.